Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Item
http://www.wikidata.org/entity/Q33430547
Epigenetics in liver disease: from biology to therapeuticsPhase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma.YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitorLooking Beyond Sorafenib to Treat Advanced Hepatocellular Carcinoma.A20 enhances the radiosensitivity of hepatocellular carcinoma cells to 60Co-γ ionizing radiation.Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10.Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis
P2860

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Item
http://www.wikidata.org/entity/Q33430547
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Resminostat plus sorafenib as ...... carcinoma - The SHELTER study.
@ast
Resminostat plus sorafenib as ...... carcinoma - The SHELTER study.
@en
type
label
Resminostat plus sorafenib as ...... carcinoma - The SHELTER study.
@ast
Resminostat plus sorafenib as ...... carcinoma - The SHELTER study.
@en
prefLabel
Resminostat plus sorafenib as ...... carcinoma - The SHELTER study.
@ast
Resminostat plus sorafenib as ...... carcinoma - The SHELTER study.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Resminostat plus sorafenib as ...... carcinoma - The SHELTER study
@en
P2093
P304
P31
P356
10.1016/J.JHEP.2016.02.043
P433
P478
P50
P577
P698